Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Current Leases (2020 - 2025)

Anaptysbio (ANAB) has disclosed Current Leases for 6 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases rose 8.05% year-over-year to $2.1 million, compared with a TTM value of $2.1 million through Dec 2025, up 8.05%, and an annual FY2025 reading of $2.1 million, up 8.05% over the prior year.
  • Current Leases was $2.1 million for Q4 2025 at Anaptysbio, up from $2.0 million in the prior quarter.
  • Across five years, Current Leases topped out at $2.1 million in Q4 2025 and bottomed at $555000.0 in Q2 2021.
  • Average Current Leases over 5 years is $1.7 million, with a median of $1.7 million recorded in 2023.
  • The sharpest move saw Current Leases skyrocketed 340.06% in 2021, then increased 8.05% in 2025.
  • Year by year, Current Leases stood at $1.5 million in 2021, then grew by 8.77% to $1.6 million in 2022, then increased by 8.55% to $1.8 million in 2023, then rose by 8.33% to $1.9 million in 2024, then increased by 8.05% to $2.1 million in 2025.
  • Business Quant data shows Current Leases for ANAB at $2.1 million in Q4 2025, $2.0 million in Q3 2025, and $2.0 million in Q2 2025.